3HAA for Health & Longevity

Evidence Review created on 07/30/2026 using AI4L / Opus 4.8

Also known as: 3-Hydroxyanthranilic Acid, 3-HAA, 3-HANA, 3-Hydroxyanthranilate, 2-Amino-3-hydroxybenzoic Acid

Motivation

3HAA (3-hydroxyanthranilic acid) is a small molecule the body makes as it breaks down tryptophan, an essential amino acid obtained from protein in food. It is not a vitamin, drug, or supplement but a natural in-between product of everyday metabolism. Interest in it has grown because it sits at a busy crossroads of chemistry that links nutrition, the immune system, and the way cells cope with stress.

For decades this molecule was seen mainly as a short-lived and possibly harmful byproduct, because in a test tube it can either mop up or generate damaging reactive particles depending on the conditions. That picture began to shift when researchers noticed that its levels change with age and that raising it in laboratory animals — worms and mice — was tied to longer, healthier lives. Blood levels also tend to fall as people grow older and to rise again with regular exercise.

This review examines what is known about 3HAA through the lens of healthy aging: how it works in the body, what benefits and risks the current evidence suggests, how its levels can be influenced, and how much of the animal research has, and has not, yet been shown in humans.

Benefits - Risks - Protocol - Conclusion

Grokipedia

3-Hydroxyanthranilic acid

Grokipedia’s encyclopedia entry summarizes 3HAA’s chemistry and molecular structure, its position within the tryptophan–kynurenine pathway, and its emerging links to aging, oxidative stress, and immune regulation.

Examine

No dedicated Examine article exists for 3HAA. Examine focuses on dietary supplements and nutrients backed by human evidence, and 3HAA is an endogenous tryptophan metabolite that is not sold or studied as a consumer supplement.

ConsumerLab

No dedicated ConsumerLab article exists for 3HAA. ConsumerLab tests commercially available consumer supplements for quality, and 3HAA is not marketed as such a product, so there is no report to reference.

Systematic Reviews

The systematic reviews and meta-analyses below analyze the kynurenine pathway as a whole and each reports pooled data on 3HAA specifically.

Kynurenine pathway dysregulation in cognitive impairment and dementia: a systematic review and meta-analysis - Choe et al., 2026

A large meta-analysis of 98 studies finding that blood 3HAA is significantly lower in Alzheimer’s dementia and challenging the older assumption that pathway metabolites are simply neurotoxic.

A systematic review and meta-analysis of the kynurenine pathway of tryptophan metabolism in rheumatic diseases - Mangoni & Zinellu, 2023

A pooled analysis of kynurenine-pathway metabolites, 3HAA included, in rheumatic (autoimmune joint) diseases, relevant to the metabolite’s role in regulating inflammation and immunity.

Dynamic changes in metabolites of the kynurenine pathway in Alzheimer’s disease, Parkinson’s disease, and Huntington’s disease: A systematic Review and meta-analysis - Fathi et al., 2022

A meta-analysis of 30 studies (689 patients, 774 controls) tracking how pathway metabolites, among them 3HAA, shift across the major neurodegenerative diseases.

Mechanism of Action

3HAA is a downstream product of the kynurenine pathway, the route that handles the large majority of dietary tryptophan. Tryptophan is first opened up by the enzymes indoleamine 2,3-dioxygenase (IDO, switched on by inflammation) and tryptophan 2,3-dioxygenase (TDO, active mainly in the liver). Several steps later, kynurenine monooxygenase (KMO) and then kynureninase produce 3-hydroxykynurenine and finally 3HAA. 3HAA is itself consumed by the enzyme 3-hydroxyanthranilate 3,4-dioxygenase (HAAO), which converts it toward quinolinic acid and ultimately nicotinamide adenine dinucleotide (NAD⁺, a coenzyme central to energy production), or toward picolinic acid.

The metabolite’s biology is genuinely two-sided, and competing mechanistic accounts coexist:

Protective / antioxidant account: 3HAA activates Nrf2 (in worms, its counterpart SKN-1), a master switch for the cell’s antioxidant defenses, and induces heme oxygenase-1 (HO-1), a protective, anti-inflammatory enzyme. It restrains inflammatory signaling, shifts the balance of immune T cells from pro-inflammatory T-helper 17 (Th17) cells toward regulatory T (Treg) cells, and can block ferroptosis — a form of iron-dependent cell death — by binding the iron-storage protein ferritin heavy chain 1 (FTH1) and disrupting its interaction with the cargo receptor NCOA4. In the lifespan work, raising 3HAA increased resistance to oxidative stress, which appears to be the core longevity-relevant action.
Damaging / pro-oxidant account: Under the right conditions 3HAA auto-oxidizes, generating hydrogen peroxide and other reactive oxygen species (ROS, unstable molecules that can damage cells), and it can reduce copper and iron to more reactive forms. This can cause DNA damage, drive cells into senescence, and contribute to protein cross-linking.

Which face dominates depends on concentration, the local redox environment, and the presence of transition metals — a key reason its net effect differs between tissues and models.

Key pharmacological properties. 3HAA is a small, water-soluble organic acid (2-amino-3-hydroxybenzoic acid) rather than a receptor-targeted drug; its actions run through redox chemistry, Nrf2/HO-1 signaling, and metal interactions rather than through a single binding site. It is a short-lived intermediate that is rapidly oxidized by HAAO, and no formal human half-life has been established. It is produced in the liver, in immune cells such as macrophages and microglia, and elsewhere; it circulates in blood, crosses into the central nervous system (CNS), and is even detectable in sweat. Its principal metabolic fate is enzymatic conversion by HAAO, alongside non-enzymatic oxidation.

Historical Context & Evolution

3HAA has no “original intended use” in the way a drug does — it was identified in the mid-twentieth century simply as one of several intermediates as biochemists mapped how the body converts tryptophan into NAD⁺ through the kynurenine pathway. For most of that history it drew attention chiefly as a suspected troublemaker: because it can generate reactive oxygen species and reduce metals in a test tube, it was grouped with 3-hydroxykynurenine and quinolinic acid as a potentially neurotoxic, pro-oxidant byproduct, and much early work focused on its possible role in cataract formation and neurodegeneration.

The reason it came to be considered for health optimization is more recent. Studies from 2011 onward described distinctly anti-inflammatory and tissue-protective actions — suppression of inflammatory signaling, induction of the protective enzyme HO-1, and reduced atherosclerosis and lipid levels in mice. The pivotal turn came in 2023, when work in roundworms and mice reported that raising physiological 3HAA extended lifespan and delayed age-related decline, reframing the molecule as a possible longevity mediator rather than merely a hazard.

The historical findings on 3HAA’s pro-oxidant chemistry have not been overturned; rather, the field’s understanding has broadened. The same molecule can be protective at physiological levels and in an antioxidant setting, yet damaging at high concentrations or in the presence of excess metals. The current, more favorable view should be read as an evolving synthesis: the balance of evidence has shifted, but the older observations still stand, and how the two reconcile in humans remains open.

Expected Benefits

Nearly all direct benefit evidence for 3HAA comes from cell, worm, and rodent studies plus mechanistic reasoning; human data are limited to observational associations of naturally occurring levels. Benefits are therefore graded conservatively, and are framed for health- and longevity-oriented adults for whom the practical question is whether and how endogenous 3HAA can be favorably influenced.

Low 🟩

Cellular Stress Resistance & Antioxidant Defense

3HAA switches on the Nrf2/SKN-1 antioxidant program and induces the protective enzyme HO-1, increasing cells’ ability to withstand oxidative stress. In roundworms this heightened stress resistance tracked closely with the lifespan benefit, and induction of HO-1 has been confirmed in mammalian astrocytes and in mouse brain. The evidence basis is replicated animal and cell work with a clear mechanism, but no human intervention has tested it, and the same chemistry can turn pro-oxidant under different conditions.

Magnitude: Not quantified in available studies.

Immune Regulation & Anti-Inflammatory Activity

3HAA dampens inflammatory signaling and rebalances immunity — reducing inflammatory Th17 activity while favoring regulatory Treg cells, restraining dendritic-cell activation, and quieting cytokine output. This has been shown across several disease models, including autoimmune inflammation, colitis-like states, and, in combination with a beneficial gut bacterium (Butyricicoccus pullicaecorum), a rat model of post-menopausal bone loss. Human relevance is supported only indirectly, by meta-analyses showing pathway metabolites shift in autoimmune and neurodegenerative disease.

Magnitude: Not quantified in available studies.

Cardiovascular & Lipid-Modulating Effects

In atherosclerosis-prone mice lacking the receptor for LDL (low-density lipoprotein, the main cholesterol-carrying particle), eight weeks of 3HAA treatment reduced aortic plaque size, lowered plasma cholesterol and triglycerides, and blocked uptake of oxidized LDL by macrophages, likely through effects on fat-metabolism regulators (PPARs, nuclear receptors that control lipid handling). The finding is mechanistically coherent and published in a leading cardiology journal, but it rests on a single interventional animal study, with human evidence limited to associations between pathway activity and cardiovascular disease.

Magnitude: Not quantified in available studies.

Speculative 🟨

Healthspan & Lifespan Extension

This is the headline claim and the reason 3HAA is of longevity interest. Lowering the clearing enzyme HAAO, or feeding 3HAA directly, extended lifespan by about 30% in Caenorhabditis elegans and delayed age-associated functional decline; pilot data in female Haao-knockout mice and aging male mice fed 3HAA pointed the same way. The proposed mechanism is enhanced oxidative-stress resistance via Nrf2/SKN-1. Because the outcome data are confined to invertebrates and small mouse pilots, with no human lifespan or healthspan evidence, this is graded speculative.

Neuroprotection & Protein-Aggregation Defense

3HAA reduced inflammation-driven neuronal death in human brain-cell cultures and, in worm models of Alzheimer’s- and Huntington’s-type protein toxicity, delayed the onset of paralysis — an effect reproduced by raising 3HAA and seemingly independent of clearing the protein clumps themselves. The basis is mechanistic and invertebrate work only, so despite biological plausibility this remains speculative for humans.

In a rat model of oxygen-injury lung disease, nebulized 3HAA improved lung development and suppressed ferroptosis by binding the iron-storage protein FTH1, and a 3HAA-based analog protected heart muscle from reperfusion injury through the same iron-death pathway. These are single-model preclinical findings that suggest a protective role in oxidative tissue injury but have not been tested in humans.

Benefit-Modifying Factors

Genetic variation in pathway enzymes: Common differences in the genes for HAAO, KYNU (kynureninase), and KMO shift how much 3HAA a person makes and how fast it is cleared; lower HAAO activity would be expected to raise steady-state 3HAA and, by analogy to the animal work, could amplify any benefit.
Baseline biomarker levels: People who start with low circulating 3HAA (which is common with older age) or with high pathway activity may have the most room to benefit from measures that raise it, whereas those already at higher levels have less headroom.
Sex-based differences: The mouse lifespan signal was sex-dependent — females benefited from removing the clearing enzyme, while aging males responded to dietary 3HAA — suggesting that the most effective route to benefit may differ between men and women.
Pre-existing health conditions: Chronic inflammation (from autoimmune disease, obesity, or infection) drives more tryptophan down this pathway, changing the baseline against which any added benefit is measured.
Age-related considerations: Blood 3HAA generally declines with age, so middle-aged and older adults — the group most relevant to longevity goals — may stand to gain most from restoring it; the animal benefits were specifically seen in the context of aging.

Potential Risks & Side Effects

There is no human safety database for 3HAA taken as an intervention, because it is not used as a medicine or supplement. The risks below come from cell and animal studies and from the metabolite’s well-documented pro-oxidant chemistry, and are framed for adults who might consider trying to raise their levels.

Low 🟥

Pro-Oxidant Activity & Oxidative Cytotoxicity

The same molecule that can bolster antioxidant defenses can, at higher concentrations or in the presence of copper or iron, generate hydrogen peroxide and reactive oxygen species that damage cells. This chemistry has been shown repeatedly in cell and biochemical studies, including copper-dependent toxicity in brain-cell cultures and reduction of metal ions that promotes protein cross-linking in the eye lens. Severity is concentration- and context-dependent, which is precisely why uncontrolled supraphysiological dosing is a concern.

Magnitude: Not quantified in available studies.

Impaired Bone Formation & Reduced Bone Density ⚠️ Conflicted

The evidence here points in opposite directions. In one 2026 study, 3HAA (and its precursor 3-hydroxykynurenine) triggered DNA damage and oxidative stress in bone-building cells, blunted their maturation, and — when given to mice — lowered whole-body bone mineral density (BMD) and cortical bone mass. Yet a separate rat study found that 3HAA combined with a gut bacterium prevented post-menopausal bone loss by rebalancing immune cells. The conflict may reflect differences in dose, delivery, and model, and it is unresolved; the possibility of net harm to bone, especially cortical bone, cannot be dismissed.

Magnitude: Not quantified in available studies.

Speculative 🟨

DNA Damage & Cellular Senescence at High Levels

In bone-lineage cells, 3HAA produced dose-dependent DNA damage that pushed cells into senescence at lower concentrations and into cell death at higher ones, with both rescued by the antioxidant N-acetylcysteine. Whether the concentrations used are reachable in human tissues through any realistic exposure is unknown, so this is a speculative, mechanism-based concern.

Shunting Toward Neurotoxic Quinolinic Acid

3HAA is the direct precursor, via HAAO, of quinolinic acid — an N-methyl-D-aspartate (NMDA) receptor agonist that is excitotoxic to neurons at high levels. In theory, strategies that flood the pathway could raise quinolinic acid alongside 3HAA; strategies that instead block HAAO would be expected to lower it. This trade-off has not been characterized in humans.

Unknown Human Safety & Absence of Human Dosing Data

No human study has administered 3HAA, so there is no established safe dose, no data on long-term exposure, and no information on interactions or effects in pregnancy, in children, or in people with organ impairment. This uncertainty is itself a meaningful risk for anyone contemplating self-experimentation with research-grade material.

Risk-Modifying Factors

Genetic antioxidant capacity: Variants that weaken the Nrf2 antioxidant response, or that impair handling of copper and iron, would be expected to tip 3HAA toward its damaging, pro-oxidant behavior.
Baseline metal and redox status: High iron stores (elevated ferritin) or copper excess provide the transition metals that convert 3HAA’s chemistry from protective to harmful; a pro-oxidant baseline raises risk.
Sex-based differences: The clearest bone-harm signal was demonstrated in a context relevant to post-menopausal women, who already face accelerated bone loss and may be more vulnerable to any negative effect on bone.
Pre-existing health conditions: People with cataract-prone lens changes, active neurodegenerative disease, or metal-overload disorders may be more susceptible to the metabolite’s oxidative and downstream neurotoxic chemistry.
Age-related considerations: Older adults may clear and buffer reactive metabolites less efficiently and are more likely to carry higher iron stores and lower antioxidant reserve, plausibly widening the margin for harm at the older end of the target range.

Key Interactions & Contraindications

Because 3HAA is not a marketed agent, the interactions below are mechanism-based rather than documented in human pharmacovigilance, and should be read as cautions.

Kynurenine-pathway drugs: IDO/TDO inhibitors (indoleamine/tryptophan dioxygenase blockers such as epacadostat and linrodostat) act upstream and would alter flux into 3HAA. Severity: caution — combining could unpredictably raise or lower downstream metabolites; monitor if ever co-used in a research setting.
Cancer immunotherapy: Because 3HAA is immunosuppressive, it could in principle blunt immune-checkpoint inhibitors (pembrolizumab, nivolumab). Severity: relative contraindication in active cancer immunotherapy; clinical consequence is reduced anti-tumor immunity. Mitigation: avoid deliberate 3HAA elevation during such treatment.
Pro-oxidant metals (over-the-counter): Iron and copper supplements, and high-dose vitamin C taken with iron, supply the metals that drive 3HAA’s radical-generating chemistry. Severity: caution; consequence is increased oxidative stress. Mitigation: separate timing and avoid unnecessary iron/copper loading.
NAD⁺-boosting supplements: Nicotinamide riboside and nicotinamide mononucleotide feed the same terminal pathway; their combined effect with 3HAA on metabolite balance is uncharacterized. Severity: monitor.
Tryptophan and 5-HTP supplements: 5-HTP (5-hydroxytryptophan) and tryptophan add substrate; extra substrate can increase overall pathway output, including potentially neurotoxic quinolinic acid. Severity: caution; mitigation is to avoid stacking high-dose tryptophan loading with pathway-elevating strategies.
Vitamin B6 status: Vitamin B6 is the cofactor for kynureninase, the enzyme that makes 3HAA’s immediate precursor; both deficiency and mega-dosing shift pathway flux. Severity: monitor; mitigation is to maintain sufficiency rather than excess.
Additive anti-inflammatory / immunosuppressive agents: Supplements and drugs that independently suppress immunity or inflammation — systemic corticosteroids (prednisone, dexamethasone), other immunosuppressants (methotrexate, cyclosporine, tacrolimus), high-dose curcumin, or omega-3s — could have additive effects with 3HAA’s own immune-quieting action. Severity: caution in already immunosuppressed individuals.
Populations who should avoid deliberate 3HAA elevation: people with active solid-tumor cancer on immune-checkpoint inhibitor therapy; pregnant or breastfeeding individuals (no data); people with iron- or copper-overload disorders (hereditary hemochromatosis with transferrin saturation >45%, or Wilson’s disease); and post-menopausal women or others with established osteopenia (bone-density T-score < −1.0) given the unresolved bone-harm signal.

Risk Mitigation Strategies

Favor physiological over pharmacological elevation: Because harms cluster at high, supraphysiological concentrations, raising 3HAA gently through lifestyle (see the exercise data below) rather than ingesting research-grade material avoids the oxidative-toxicity, DNA-damage, and senescence risks tied to concentrated dosing.
Correct metal status first: To limit the pro-oxidant, hydrogen-peroxide–generating chemistry, check and normalize iron and copper before any attempt to raise 3HAA — targeting ferritin roughly 50–150 ng/mL and avoiding unnecessary iron or copper supplements.
Maintain antioxidant reserve: Ensuring adequate glutathione precursors — for example N-acetylcysteine (NAC, a precursor to the antioxidant glutathione) — directly counters the reactive-oxygen-species mechanism that rescued cells from 3HAA-induced damage in the laboratory.
Protect bone in at-risk groups: Given the conflicting bone data, anyone post-menopausal or with low bone density who considers pathway manipulation should monitor bone-mineral density every 1–2 years and maintain calcium, vitamin D, and resistance exercise to offset the possible reduction in bone formation.
Keep vitamin B6 at sufficiency, not excess: Because B6 governs the enzyme feeding 3HAA production, keeping plasma levels in the sufficient range (roughly 30–110 nmol/L) rather than mega-dosing avoids unpredictable shifts in pathway flux.
Avoid stacking substrate and pathway loads: Not combining high-dose tryptophan or 5-HTP with other pathway-elevating measures limits the risk of driving neurotoxic quinolinic acid production downstream.

Therapeutic Protocol

There is no validated human protocol for 3HAA. What follows describes the approaches used in research and the main competing strategies, none of which is established for human use.

Approach 1 — Direct dietary supplementation: In the foundational aging work, aging mice were fed a 3HAA-supplemented diet; exact human-equivalent doses have not been determined, and no human dosing regimen exists. This approach was popularized by the laboratory of George Sutphin, whose group first reported the lifespan effect.
Approach 2 — Inhibiting the clearing enzyme (HAAO): Rather than adding 3HAA, this strategy raises endogenous levels by slowing its breakdown; it produced the largest lifespan effect in animals but depends on drug-like HAAO inhibitors that are not clinically available.
Approach 3 — Lifestyle elevation (exercise): In middle-aged adults, 26 weeks of endurance exercise raised serum 3HAA by 85–134%; this is the only route demonstrated to move 3HAA in humans and is presented alongside the pharmacological approaches without being framed as equivalent in effect.
Best time of day: Not established; no chronobiology data exist for 3HAA administration.
Half-life and dosing frequency: 3HAA is a short-lived intermediate that is rapidly oxidized, with no formal human half-life reported; whether single or split dosing would be appropriate is therefore unknown.
Genetic considerations: Variants in HAAO, KYNU, and KMO could influence the dose or approach most likely to raise 3HAA effectively, but no pharmacogenetic guidance exists.
Sex-based differences: Animal data suggest enzyme inhibition may suit females and dietary 3HAA may suit males, hinting that the optimal approach could be sex-specific.
Age-related considerations: Because baseline 3HAA falls with age, older adults may require a larger relative increase to reach youthful levels, though target levels are undefined.
Baseline biomarker levels: Measuring pathway metabolites before and after any change (see Monitoring) is the only rational way to gauge response in the absence of a validated dose.
Pre-existing conditions: Inflammatory states, cancer, and metal-overload disorders should shape whether pathway elevation is advisable at all.

Discontinuation & Cycling

Lifelong versus short-term: Not established. As an endogenous metabolite there is no defined treatment course; lifestyle measures that raise it (exercise) are inherently ongoing, whereas any hypothetical supplementation has no studied duration.
Withdrawal effects: None are known or expected; stopping a measure that raises 3HAA would simply allow levels to return toward baseline as the metabolite is rapidly cleared.
Tapering: Not applicable given the short half-life and the absence of any dependence or rebound phenomenon in the available data.
Cycling: Whether cycling would preserve any benefit or limit oxidative risk is entirely untested; no cycling recommendation can be supported.

Sourcing and Quality

This section is largely not applicable in the usual sense, because 3HAA is not sold as a human supplement; the notes below explain the sourcing reality.

No consumer-grade product exists: 3HAA is available only as a laboratory reagent from chemical suppliers (for example MilliporeSigma/Sigma-Aldrich, TCI, and Cayman Chemical), sold for research use and not for human consumption.
What “research grade” means: Such material is typically specified at ≥98% purity but is not manufactured, tested, or labeled to food- or pharmaceutical-grade standards, and may carry solvent residues or contaminants irrelevant to bench use but relevant to ingestion.
Third-party testing: No independent, consumer-facing quality certification (of the kind used for mainstream supplements) applies to 3HAA, so purity and identity cannot be verified by the standards a proactive user would normally expect.
Reputable formulations / compounding: There are no reputable human-grade brands or compounding pharmacies producing 3HAA for people; the practical way to influence 3HAA is through endogenous production rather than a purchased product.

Practical Considerations

Time to effect: Unknown in humans; in animals, lifespan and health effects developed over weeks to the remainder of life, and the human exercise study measured its 85–134% rise after six months of training.
Common pitfalls: Over-reading worm and mouse results as if proven in people; sourcing research chemicals of unverified purity for self-experimentation; and ignoring the metabolite’s dual nature, in which the same molecule can protect or damage depending on dose and metal environment.
Regulatory status: 3HAA is not approved by the U.S. Food and Drug Administration (FDA) as a drug and is not a recognized dietary-supplement ingredient; it is sold for research use only, and marketing or selling it for human consumption is not permitted.
Cost and accessibility: As a bulk reagent it is inexpensive per gram, but a legitimate, human-grade, quality-assured form is effectively inaccessible — the meaningful “access” route is lifestyle modification, not purchase.

Interaction with Foundational Habits

Sleep: Indirect. Tryptophan is shared between this pathway and the serotonin/melatonin route that supports sleep; heavy diversion of tryptophan toward kynurenine metabolites could, in theory, reduce substrate for melatonin. No direct effect of 3HAA on sleep has been demonstrated, and the practical implication is simply to maintain adequate protein and not to over-manipulate the pathway at the expense of sleep chemistry.
Nutrition: Direct and potentiating on the supply side. Dietary tryptophan (from protein) feeds the entire pathway, and B-vitamin cofactors — vitamin B6 for kynureninase and riboflavin for upstream steps — are required to produce 3HAA. The practical consideration is sufficiency, not excess: adequate protein and B-vitamin status support normal 3HAA production, while mega-dosing tryptophan or B6 can distort pathway flux.
Exercise: Direct and potentiating, and the best-supported lever in humans. Endurance training raised serum 3HAA by 85–134% over 26 weeks regardless of whether intensity was increased or held moderate, making regular aerobic exercise the one evidence-based way to raise 3HAA in people.
Stress management: Indirect. Psychological and physiological stress raise cortisol and inflammatory signaling, which activate IDO and push more tryptophan down the kynurenine pathway; chronic stress therefore shifts metabolite balance, and stress reduction helps keep that flux in a healthier range rather than being a way to “boost” 3HAA per se.

Monitoring Protocol & Defining Success

Because 3HAA is not a standard clinical target, monitoring centers on the pathway it belongs to and on the body systems the evidence flags for benefit or harm. Before any attempt to influence 3HAA, a baseline panel should establish pathway activity, inflammation, metal status, and bone health; the kynurenine-to-tryptophan ratio (KTR) and high-sensitivity C-reactive protein (hs-CRP) anchor that assessment.

Ongoing monitoring on a cadence of roughly every 6–12 months — or a focused recheck at 8–12 weeks after a deliberate change such as starting a structured exercise program — is reasonable, with bone density reassessed every 1–2 years where the bone-loss concern applies.

Biomarker	Optimal Functional Range	Why Measure It?	Context/Notes
Serum 3-hydroxyanthranilic acid (3HAA)	No established optimal range (low nanomolar, assay-dependent)	Direct level of the metabolite of interest	Not offered by routine labs; requires a specialized laboratory assay (high-performance liquid chromatography or mass spectrometry). Levels tend to fall with age and rise with exercise.
Kynurenine-to-tryptophan ratio	~20–40 (µmol/mmol); lower is generally more favorable	Reflects activity of the pathway that feeds 3HAA	Rises with inflammation and age; interpret together with hs-CRP.
Serum tryptophan	45–80 µmol/L	Substrate availability for the whole pathway	Draw fasting in the morning; varies with protein intake and time of day.
Kynurenine	1.4–2.5 µmol/L	Upstream precursor and marker of pathway flux	Elevated by inflammation and cortisol.
High-sensitivity C-reactive protein	<1.0 mg/L	Systemic inflammation that drives flux into this pathway	Conventional labs treat <3.0 mg/L as normal, so the functional target is stricter; do not test during acute illness.
Ferritin	50–150 ng/mL	Iron stores; excess iron amplifies 3HAA’s pro-oxidant chemistry	Conventional upper limit (~300–400 ng/mL) runs far higher than the functional optimum; it is an acute-phase reactant, so pair with hs-CRP.
Serum copper	70–110 µg/dL	Copper can drive 3HAA-related free-radical damage	Check with ceruloplasmin if metal overload is suspected.
Vitamin B6 (plasma PLP)	30–110 nmol/L	Cofactor for the enzyme making 3HAA’s precursor	PLP is pyridoxal 5′-phosphate, the active form of vitamin B6; correct deficiency but avoid mega-dosing.
Bone mineral density (T-score)	≥ −1.0	Screens for the bone-loss risk suggested by animal data	Measured by DXA (dual-energy X-ray absorptiometry); establish a baseline especially for post-menopausal women.

Qualitative markers to track alongside the labs:

Energy and vitality: day-to-day energy levels and sense of stamina.
Exercise recovery: how quickly one recovers from and adapts to training, given exercise is the main lever.
Cognitive clarity: subjective focus and mental sharpness.
Inflammatory symptoms: joint comfort, stiffness, and general inflammatory burden.
Sleep quality: restfulness and continuity of sleep, given the shared tryptophan supply.

Emerging Research

Research on 3HAA is early and moving on several fronts; the studies below include work that could strengthen the case for it and work that could weaken it.

No registered interventional trials: As of 2026-07-30, a ClinicalTrials.gov search returns no interventional trial testing 3HAA supplementation or HAAO inhibition in humans; the closest registered work only measures tryptophan metabolites observationally. Pathway-targeted human trials to date have focused on upstream enzyme inhibitors rather than 3HAA itself, as reviewed in Recent advances in clinical trials targeting the kynurenine pathway (Pires et al., 2022).
Human translation via exercise: Joisten et al., 2025 established that exercise raises human 3HAA and that levels fall with age — a strengthening line of evidence that a lifestyle route exists.
Non-invasive biomarker development: Katewongsa et al., 2024 reported the first detection of 3HAA in human sweat and its rise with age, pointing toward easier monitoring tools.
Gut-microbiome regulation: Castells-Nobau et al., 2026 linked gut microbial production of 3HAA to dopamine signaling and attention in obesity, opening a microbiome-based avenue to modulate it.
Bone-safety signal (weakening evidence): Alhamad et al., 2026 reported that 3HAA impairs bone formation and lowers bone density in mice, a finding that must be resolved before human use could be considered.
Cancer immunometabolism (cautionary direction): Xue et al., 2023 showed 3HAA reshapes tumor macrophages in liver cancer, a reminder that its immune-suppressing action could be unwanted in a cancer setting.
Analog and delivery development: Yang et al., 2025 reported a 3HAA analog that protected heart tissue from reperfusion injury via anti-ferroptosis signaling, suggesting engineered derivatives may follow.
Key open questions: whether raising 3HAA in humans reproduces the animal healthspan benefits, what a safe dose and exposure would be, and how to keep its antioxidant face dominant over its pro-oxidant one — none of which current published evidence answers.

Conclusion

3HAA is a natural molecule the body makes while breaking down a common dietary amino acid. It has moved from being seen as a throwaway, possibly harmful byproduct to a candidate worth studying for healthy aging, largely because raising it helped small laboratory animals live longer and stay healthier, apparently by strengthening how cells resist stress and by calming inflammation. There are hints of wider benefits for blood vessels, the brain, and tissue protection, and one human study shows that regular endurance exercise reliably raises its levels, which otherwise tend to fall with age.

The evidence, however, is still early and one-sided in an important way: the benefits come almost entirely from cells, worms, and mice, while no human trial has ever given people this molecule. At the same time, the very chemistry that makes it useful can turn damaging at high amounts or alongside excess iron and copper, and there are unsettled signals of harm to bone. It is also not available as a quality-assured product for people.

For someone focused on longevity, the balance of current evidence casts 3HAA as a promising but still unproven lead. Its biology is genuinely interesting, and the one everyday habit clearly tied to higher levels is consistent exercise, yet the human evidence that would confirm a true benefit — or rule out harm — is still absent, leaving its real value an open question.

Top - Benefits - Risks - Protocol

3HAA for Health & Longevity

Motivation

Recommended Reading

Grokipedia

Examine

ConsumerLab

Systematic Reviews

Mechanism of Action

Historical Context & Evolution

Expected Benefits

Low 🟩

Cellular Stress Resistance & Antioxidant Defense

Immune Regulation & Anti-Inflammatory Activity

Cardiovascular & Lipid-Modulating Effects

Speculative 🟨

Healthspan & Lifespan Extension

Neuroprotection & Protein-Aggregation Defense

Protection Against Ferroptosis-Related Tissue Injury

Benefit-Modifying Factors

Potential Risks & Side Effects

Low 🟥

Pro-Oxidant Activity & Oxidative Cytotoxicity

Impaired Bone Formation & Reduced Bone Density ⚠️ Conflicted

Speculative 🟨

DNA Damage & Cellular Senescence at High Levels

Shunting Toward Neurotoxic Quinolinic Acid

Unknown Human Safety & Absence of Human Dosing Data

Risk-Modifying Factors

Key Interactions & Contraindications

Risk Mitigation Strategies

Therapeutic Protocol

Discontinuation & Cycling

Sourcing and Quality

Practical Considerations

Interaction with Foundational Habits

Monitoring Protocol & Defining Success

Emerging Research

Conclusion